Why the study?
Does intravenous tenoxicam 40 mg reduce pain and opioid consumption in ASA Grade I/II patients after abdominal or orthopaedic surgery?
Does intravenous tenoxicam 40 mg reduce pain and opioid consumption in ASA Grade I/II patients after abdominal or orthopaedic surgery?
Intravenous tenoxicam 40 mg effectively reduces post-operative morphine requirements while maintaining adequate analgesia and a favorable safety profile in patients undergoing abdominal or orthopaedic surgery.
Answers are grounded in this paper and cite their sources.
Supports adding IV tenoxicam to multimodal regimens to reduce postoperative opioid needs; extends RCT evidence for perioperative NSAID opioid-sparing effects.
The analgesic efficacy of tenoxicam, a newer injectable non-steroidal anti-inflammatory drug, for post-operative analgesia after abdominal or orthopaedic surgery in ASA Grade I/II patients is reported. Two hundred and fifty-six patients received a single dose of tenoxicam 40 mg intravenous (i.v.) at the end of surgery and this was repeated 24h later. These patients were compared, with respect to pain or adverse events, with 258 patients that received placebo. All patients were monitored for the next 72 h. Overall, tenoxicam provided reliable analgesia with comparable pain scores at rest, moving and coughing. The cumulative rescue PCA-morphine consumption was always lower in the tenoxicam treated patients and was most marked at 4 and 24h after the second injection of tenoxicam. This effect was more pronounced after abdominal surgery. The intravenous administration of tenoxicam was associated with a low incidence of adverse events and a high tolerability.
No takes yet. Share an insight, caveat, or question.
Vandermeulen et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: